학술논문

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Document Type
Article
Source
In Annals of Oncology February 2017 28(2):313-320
Subject
Language
ISSN
0923-7534